{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:20:24Z","timestamp":1776788424790,"version":"3.51.2"},"reference-count":32,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2651037","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:32:43Z","timestamp":1776785563000},"page":"1198-1212","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Gu\u00e9rin\u2013unresponsive, high-risk, non\u2013muscle-invasive bladder cancer with carcinoma in situ in the United States"],"prefix":"10.1080","volume":"29","author":[{"given":"Stephen","family":"Williams","sequence":"first","affiliation":[{"name":"University of Texas Medical Branch Clear Lake","place":["Webster, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang","family":"Cho","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Morrison","sequence":"additional","affiliation":[{"name":"Analysis Group ULC","place":["Montreal, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kruti","family":"Joshi","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[{"name":"Analysis Group ULC","place":["Montreal, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayleen","family":"Gwyn","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Libchaber","sequence":"additional","affiliation":[{"name":"Analysis Group ULC","place":["Montreal, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Wong","sequence":"additional","affiliation":[{"name":"Analysis Group ULC","place":["Montreal, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Lee","sequence":"additional","affiliation":[{"name":"Analysis Group ULC","place":["Montreal, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urvi","family":"Desai","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul","family":"Singhal","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_3_8_2_1","unstructured":"National cancer institute surveillance epidemiology and end results program. Cancer Stat Facts Bladder Cancer. 2025. :cited 2025 August 6]. Available fromhttps:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1170124"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040636"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6051.22.04953-9"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12030586"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.11.010"},{"issue":"1","key":"e_1_3_8_9_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.urolonc.2020.07.011","article-title":"\u201cReal-world\u201d outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma","volume":"39","author":"Drakaki A","year":"2021","unstructured":"Drakaki A, Pantuck A, Mhatre SK, et al. \u201cReal-world\u201d outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. Urol Oncol. 2021;39(1):76 e15\u201376 e22.","journal-title":"Urol Oncol"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3800"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01616-3"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.12.117"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.09.031"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16091154"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.04.010"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167"},{"key":"e_1_3_8_19_1","volume-title":"American urological association annual meeting","author":"Jacob J","year":"2025","unstructured":"Jacob J, Guerrero-Ramos F, Necchi A, et al. TAR-200 monotherapy in patients with bacillus calmette-gu\u00e9rin\u2013unresponsive high-risk non\u2013muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from sunrise-1. American urological association annual meeting. 2025., editors. Las Vegas, NV, USA."},{"key":"e_1_3_8_20_1","unstructured":"Johnson J. U.S. FDA approval of INLEXZO\u2122 (gemcitabine intravesical system) set to transform how certain bladder cancers are treated. 2025. [cited 2025 September 23]. Available fromhttps:\/\/www.jnj.com\/media-center\/press-releases\/u-s-fda-approval-of-inlexzo-gemcitabine-intravesical-system-set-to-transform-how-certain-bladder-cancers-are-treated."},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.09.4137"},{"key":"e_1_3_8_22_1","unstructured":"Centers for medicare & medicaid services. ASP drug pricing files [cited 2025 March 31]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files."},{"key":"e_1_3_8_23_1","unstructured":"Merative. Wholesale acquisition cost (WAC) pricing [cited 2025 October 31]. Available from: https:\/\/www.merative.com\/documents\/micromedex-red-book."},{"key":"e_1_3_8_24_1","unstructured":"Hematology ASo. Final Physician Fee Schedule Payment Rates. January 12. 2023. Available from: https:\/\/www.hematology.org\/advocacy\/testimony-and-correspondence\/2023-final-physician-fee-schedule-payment-rates."},{"key":"e_1_3_8_25_1","unstructured":"Medicare.gov. procedure price lookup. 2024. Available fromhttps:\/\/www.medicare.gov\/procedure-price-lookup\/."},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2550-x"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102313"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.10.012"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.12.002"},{"key":"e_1_3_8_31_1","unstructured":"Johnson & Johnson. TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non\u2013muscle-invasive bladder cancer. 2024. cited 2025 September 3]. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/tar-200-monotherapy-shows-greater-than-80-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer."},{"key":"e_1_3_8_32_1","unstructured":"Ferring Pharmaceuticals. ADSTILADRIN\u00ae (nadofaragene firadenovec-vncg) highlights of prescribing information. 2024. [cited 2025 September 3]. Available from: https:\/\/ferringusa.com\/wp-content\/uploads\/sites\/12\/2024\/10\/Adstiladrin_PI.pdf."},{"key":"e_1_3_8_33_1","unstructured":"ImmunityBio Inc. ANKTIVA\u00ae (nogapendekin alfa inbakicept-pmln) highlights of prescribing information. 2024. cited 2025 September 3]. Available from: https:\/\/anktiva.com\/wp-content\/uploads\/ANKTIVA-Annotated-Approved-Label-Clean.pdf."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2651037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:32:48Z","timestamp":1776785568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2651037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2651037"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2651037","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}